Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HURA 
TuHURA Biosciences Inc (HURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: HURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.08
1 Year Target Price $12.08
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.18% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.65M USD | Price to earnings Ratio - | 1Y Target Price 12.08 |
Price to earnings Ratio - | 1Y Target Price 12.08 | ||
Volume (30-day avg) 2 | Beta - | 52 Weeks Range 1.80 - 7.20 | Updated Date 10/17/2025 |
52 Weeks Range 1.80 - 7.20 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.68% | Return on Equity (TTM) -332.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 125704901 | Price to Sales(TTM) - |
Enterprise Value 125704901 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 51103535 | Shares Floating 27702975 |
Shares Outstanding 51103535 | Shares Floating 27702975 | ||
Percent Insiders 35.79 | Percent Institutions 12.72 |
Upturn AI SWOT
TuHURA Biosciences Inc
Company Overview
History and Background
TuHURA Biosciences, Inc. (formerly known as Cytokine PharmaSciences Inc.) is a biopharmaceutical company focused on developing next generation immunotherapies to treat cancer. The company was founded in 2015 and went public in March 2024. Its evolution has been marked by preclinical and clinical stage drug development in immuno-oncology.
Core Business Areas
- Oncology: Developing and commercializing innovative cancer therapies, focusing on novel immuno-oncology approaches.
Leadership and Structure
Details about the leadership team and organizational structure are not publicly available in easily summarized form. Information can be found in regulatory filings.
Top Products and Market Share
Key Offerings
- IFNu03b12b (IL-21 activated): TuHURA Biosciences' leading investigational agent is IFNu03b12b (IL-21 activated). This is a therapy under evaluation for various cancer indications. Market share data is unavailable as this is in the developmental phase. Competitors in the immuno-oncology space include larger pharmaceutical companies with approved therapies.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing substantial growth, driven by the increasing prevalence of cancer and the demand for more effective and targeted therapies. The market is competitive, with numerous companies developing and commercializing novel immunotherapies.
Positioning
TuHURA Biosciences is positioned as a development-stage company focused on novel immuno-oncology approaches. Its competitive advantage (if any) hinges on the successful development and commercialization of its investigational agents. Given its limited pipeline information in the public domain, a detailed analysis of its competitive position is not practical.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars. TuHURA Biosciences' TAM depends on the specific indications its therapies target and its ability to capture market share. It is a small player targeting a large market.
Upturn SWOT Analysis
Strengths
- Focus on Immuno-Oncology
- Novel Investigational Agent(s)
- Experienced Management Team (assumed)
Weaknesses
- Development Stage Company
- Limited Financial Resources
- High Regulatory Risk
- No Currently Approved Products
- Small Market Cap
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Successful Clinical Trial Results
- FDA Approval of Investigational Agents
- Expansion into New Indications
Threats
- Competition from Established Pharmaceutical Companies
- Clinical Trial Failures
- Regulatory Hurdles
- Patent Infringement
- Market Volatility
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
- GILD
Competitive Landscape
TuHURA Biosciences faces intense competition from established pharmaceutical companies with significantly more resources and approved products. Its success depends on differentiating its investigational agents and securing partnerships.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data is available as a recently public company.
Future Projections: Future growth depends on successful clinical trials and regulatory approval of its investigational agents. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives likely include progressing its investigational agents through clinical trials and seeking partnerships.
Summary
TuHURA Biosciences is a development-stage company in the competitive immuno-oncology field. Its success hinges on positive clinical trial outcomes and regulatory approvals for its investigational agents. Its small size and limited resources pose challenges against larger, established competitors. Securing partnerships and demonstrating clinical efficacy are crucial for future growth. Its high-risk, high-reward profile makes it a speculative investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Public News Sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in biotech companies is highly speculative and carries significant risk. Market share data is estimated and may not be precise. The AI rating is based on a limited set of information and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TuHURA Biosciences Inc
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2013-02-22 | President, CEO & Director Dr. James A. Bianco M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.tuhurabio.com |
Full time employees 19 | Website https://www.tuhurabio.com | ||
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.